Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Curr Pharm Des. 2018;24(39):4668-4674. doi: 10.2174/1381612825666190110161843.
Angiogenesis refers to the formation of recent blood vessels, which is one of the characteristics of cancer progression and it has been deliberated as a putative target to the treatment of many kinds of cancers. The VEGF signaling substrate is very important for angiogenesis and is commonly high-regulated in tumors. As a result, this molecule has attracted the attention of most of the researchers to develop antiangiogenic therapies. We have presented that VEGF blockage in neoadjuvant setting via bevacizumab, aflibercept and sunitinib not only has revealed some promising benefits but also has shown a large negative outcome in the adjuvant trials. However, at an advanced stage of tumors, suppression of VEGF alone is inadequate to stop advancement, encouraging drug resistance, and probably enhancing metastasis and invasion in the tumor microenvironment, thereby suggesting the therapeutic potential of targeting angiogenic pathways in gastrointestinal cancers.
血管生成是指新血管的形成,这是癌症进展的特征之一,已经被认为是治疗多种癌症的潜在靶点。VEGF 信号底物对血管生成非常重要,并且在肿瘤中通常被高度调节。因此,这个分子引起了大多数研究人员的关注,以开发抗血管生成疗法。我们已经表明,贝伐单抗、阿柏西普和舒尼替尼在新辅助治疗中阻断 VEGF,不仅显示出一些有希望的益处,而且在辅助试验中也显示出了很大的负面结果。然而,在肿瘤的晚期,单独抑制 VEGF 不足以阻止进展,反而会导致耐药性,并可能增强肿瘤微环境中的转移和侵袭,这表明针对胃肠道癌症的血管生成途径具有治疗潜力。